August 27, 2007
Medicinova issued positive results from a phase Ib trial of MN-221 for the treatment of pre-term labor. This trial enrolled 10 healthy, pregnant subjects who were not in labor. The subjects received a single-dose intravenous infusion regimen of MN-221, consisting of two consecutive rounds of a 15-minute priming and a 105-minute maintenance infusion to deliver 294 micrograms of MN-221 over four hours. The primary endpoints included pharmacokinetics, safety and tolerability. Treatment was safe and well tolerated, with no reported serious adverse events. In addition, target plasma concentrations were achieved with an intravenous priming followed by maintenance infusion dosing paradigm. Based on the results, Medicinova plans to move forward with development.
July 30, 2007
Alliance reported positive results from a phase III trial of Isprelor for the induction of labor. This trial enrolled 600 women who received Isprelor (25 mg) or dinoprostone (standard of care). The study met the primary endpoint of non-inferiority. The two treatments were similarly efficacious, with no statistical difference between Isprelor and dinoprostone in the ability to produce a vaginal delivery within 24 hours of commencing treatment. No unexpected adverse events occurred and Isprelor was shown to be no more likely than dinoprostone to cause hyperstimulation of the uterus. Based on the results, Alliance planned to file for European approval in the second half of 2008.